ETOPOSIDE
Extranodal NK-T-Cell Lymphoma
Samsung Medical CenterSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Extranodal NK-T-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Busulphan Samsung Medical Center | Phase 2 | CCC |
Fludarabine Samsung Medical Center | Phase 2 | CCC |
ASPARAGINASE Samsung Medical Center | Phase 2 | CCC |
Romidepsin Samsung Medical Center | Phase 2 | CCC |
DEXAMETHASONE Samsung Medical Center | Phase 2 | CCC |
FILGRASTIM Samsung Medical Center | Phase 2 | CCC |
Ifosfamide Samsung Medical Center | Phase 2 | CCC |
Evomela Samsung Medical Center | Phase 2 | CCC |
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →